[ad_1]
The Food and Drug Administration has approved a new drug to treat the Ebola virus.
- It was tested during the 2018 Ebola epidemic and represents a glimpse of what could come with the coronavirus.
Details:
- The drug, called Inmazeb, is a mixture of three different antibodies that can block the Ebola virus.
-
Regeneron, who is currently developing an antibody treatment for COVID-19, developed the antibody mix. Those who drank the mixture were less likely to die from Ebola.
Key quotes:
- John Farley, director of the Office of Infectious Diseases at the FDA’s Center for Drug Evaluation and Research, said the FDA approval shows the importance of international collaboration in the fight against the Ebola virus. “
- Health and Human Services Secretary Alex Azar said in a statement Wednesday: “The approval of the first therapeutic treatment for Ebola is a momentous global health achievement that would never have occurred without American leadership.”
Retrospective scene:
- Inmazeb underwent clinical trials from 2018 to 2019 during an Ebola outbreak in the Democratic Republic of the Congo, according to The Verge.
- The trial compared four different drugs that were made to fight Ebola. Inmazeb and another proved to be the most effective.
- The Ebola virus infected humans in the Congo dozens of times. The virus often returns with a different stranger, infecting dozens of people in the process.
